论文部分内容阅读
目的:探讨鼠类肉瘤滤过性病毒致癌基因同源体B1(v-raf murine sarcoma viral oncogene homolog B1,BRAF)和生促红素人肝细胞蛋白(erythropoietin-producing hepatoma cell line B2,EphB2)在人结直肠锯齿状腺瘤中的表达及其意义。方法:收集滨州医学院附属医院1996年1月至2008年5月10例正常结直肠肠黏膜、21例增生性息肉、22例锯齿状腺瘤、55例腺瘤性息肉(18例管状腺瘤、16例管状绒毛状腺瘤、21例绒毛状腺瘤)石蜡标本。免疫组织化学法检测BRAF和EphB2蛋白的表达量,同时观察蛋白的表达部位。结果:增生性息肉中BRAF蛋白阳性细胞多位于隐窝中下区域,腺瘤性息肉的阳性细胞多表达位于隐窝上部区域,而锯齿状腺瘤阳性细胞多表达于隐窝全层。锯齿状腺瘤与腺瘤性息肉的BRAF蛋白表达量相近[(0.129±0.030)vs(0.130±0.026),P>0.05],但远高于增生性息肉[(0.129±0.030)vs(0.102±0.014),P<0.01];锯齿状腺瘤、管状腺瘤、管状绒毛状腺瘤、绒毛状腺瘤之间BRAF蛋白表达量差异无统计学意义[(0.129±0.030)vs(0.116±0.019),(0.119±0.037),(0.122±0.008),P>0.05]。增生性息肉中EphB2蛋白阳性细胞多位于隐窝中下区域细胞膜上,腺瘤性息肉EphB2蛋白阳性细胞位于隐窝上部,而锯齿状腺瘤EphB2蛋白阳性细胞表达于隐窝全层。锯齿状腺瘤与腺瘤性息肉的EphB2蛋白表达量相近[(0.138±0.024)vs(0.139±0.025),P>0.05],而远高于增生性息肉[(0.138±0.024)vs(0.169±0.018),P<0.01];锯齿状腺瘤与管状腺瘤、管状绒毛状腺瘤、绒毛状腺瘤间EphB2蛋白表达量无区别[(0.138±0.024)vs(0.143±0.027),(0.139±0.028),(0.133±0.021),P>0.05]。结论:BRAF和EphB2蛋白在增生性息肉、腺瘤性息肉中隐窝部分区域表达,而在锯齿状腺瘤中隐窝全层表达,提示锯齿状腺瘤是一类独立的不同于腺瘤性息肉的结直肠肿瘤。
Objective: To investigate the effect of vrf murine sarcoma viral oncogene homolog B1 (BRAF) and erythropoietin-producing hepatoma cell line B2 (EphB2) Expression of colorectal serrated adenoma and its significance. Methods: Ten cases of normal colorectal mucosa, 21 cases of hyperplastic polyps, 22 cases of serrated adenomas and 55 cases of adenomatous polyps (18 cases of tubular adenoma) were collected from Affiliated Hospital of Binzhou Medical College from January 1996 to May 2008. , 16 cases of tubular villous adenoma, 21 cases of villous adenoma) paraffin specimens. Immunohistochemistry was used to detect the expression of BRAF and EphB2 protein, and to observe the expression of protein. Results: The majority of BRAF positive cells in proliferative polyps were located in the middle and lower part of crypts. The positive cells of adenomatous polyps were mostly located in the upper part of crypts, whereas the positive ones of serrated adenomas were mostly in the whole crypts. The expression of BRAF in serrated adenomas and adenomatous polyps was significantly higher than that in proliferative polyps [(0.129 ± 0.030) vs (0.130 ± 0.026, P> 0.05] (0.129 ± 0.030) vs (0.116 ± 0.019), P <0.01]. There was no significant difference in BRAF protein expression between serrated adenoma, tubular adenoma, tubular villous adenoma and villous adenoma [ , (0.119 ± 0.037), (0.122 ± 0.008), P> 0.05]. EphB2 protein positive cells in proliferative polyps were mostly located on the cell membrane in the middle and lower subfacial regions of the crypts. EphB2 protein positive cells in the adenomatous polyps were located in the upper part of crypts, whereas serrated adenoma EphB2 protein positive cells were expressed in the entire crypts. The expression of EphB2 in serrated adenomas and adenomatous polyps was significantly higher than that in proliferative polyps [(0.138 ± 0.024) vs (0.139 ± 0.024) vs (0.139 ± 0.025), P> 0.05] 0.018), P <0.01]. There was no difference in EphB2 protein expression between serrated adenoma and tubular adenoma, tubular villous adenoma and villous adenoma [(0.138 ± 0.024) vs (0.143 ± 0.027), (0.139 ± 0.028), (0.133 ± 0.021), P> 0.05]. CONCLUSIONS: The expression of BRAF and EphB2 proteins in the crypts of proliferative polyps and adenomatous polyps, whereas the full-thickness crypts in serrated adenomas suggest that serrated adenomas are a distinct group of adenocarcinomas Polyps of colorectal cancer.